富马酸替诺福韦在治疗低病毒载量慢性乙肝患者中的效果分析  

Analysis of the Therapeutic Effect of Tenofovir Disoproxil Fumarate in Treatment-Naïve Patients with Low Viral Load Chronic Hepatitis B

作　　者：闫怡儒 张玉[1] 郭春霞[1] YAN Yiru;ZHANG Yu;GUO Chunxia(Department of Infectious Diseases,First Affiliated Hospital of Nanyang Medical College,Nanyang Henan 473000,China)

机构地区：[1]南阳医学高等专科学校第一附属医院感染性疾病科,河南南阳473000

出　　处：《临床研究》2024年第11期50-53,共4页Clinical Research

摘　　要：目的探究低病毒载量慢性乙肝(CHB)患者的治疗期间应用富马酸替诺福韦(TDF)的价值。方法选取南阳医学高等专科学校第一附属医院2021年4月至2024年1月期间医院感染性疾病科诊治的72例低病毒载量CHB患者,其均符合低病毒载量的治疗标准,依据用药计划的差异,将其分为研究组(n=36,TDF)、对照组(n=36,常规治疗),比较两组疗效、肝功能指标、肝纤维化指标以及恢复情况。结果治疗后,研究组治疗有效率(97.22%)显著高于对照组(75.00%),差异有统计学意义(P<0.05);治疗前,两组肝功能、肝纤维化指标比较差异无统计学意义(P>0.05),治疗后,两组肝功能、肝纤维化指标均降低,且研究组低于对照组,差异有统计学意义(P<0.05);治疗后,研究组乙肝病毒-脱氧核糖核酸(HBV-DNA)转阴率、乙肝e抗原(HBeAg)转阴率、血清丙氨酸氨基转移酶(ALT)复常率均高于对照组,差异有统计学意义(P<0.05)。结论低病毒载量CHB患者治疗期间应用TDF较为理想,能够提升临床疗效,改善总胆红素、ALT等肝功能相关指标,进而优化HBV-DNA转阴率、HBeAg转阴率、ALT复常率,具有临床应用意义。Objective To explore the value of applying Tenofovir Disoproxil Fumarate(TDF)in the treatment of low viral load chronic hepatitis B(CHB)patients.Methods A total of 72 low viral load CHB patients treated at the Department of Infectious Diseases of the First Affiliated Hospital of Nanyang Medical College from April 2021 to January 2024 were selected.According to different medication plans,the patients were divided into a study group(n=36,treated with TDF)and a control group(n=36,treated with conventional therapy).The efficacy,liver function indicators,liver fibrosis indicators,and recovery conditions were compared between the two groups.Results After treatment,the study group had a significantly higher treatment effective rate(97.22%)compared to the control group(75.00%),with statistical significance(P<0.05).Before treatment,there were no significant differences in liver function and liver fibrosis indicators between the two groups(P>0.05).After treatment,both groups showed decreased liver function and liver fibrosis indicators,with the study group showing significantly lower levels compared to the control group(P<0.05).The study group also had higher HBV-DNA clearance rate,HBeAg clearance rate,and ALT normalization rate compared to the control group(P<0.05).Conclusion The application of TDF in the treatment of low viral load CHB patients is ideal,as it significantly improves clinical efficacy,liver function indicators such as total bilirubin and ALT,and optimizes HBV-DNA clearance rate,HBeAg clearance rate,and ALT normalization rate,making it valuable for clinical application.

关 键 词：富马酸替诺福韦 慢性乙肝 治疗效果 低病毒载量 

分 类 号：R373.21[医药卫生—病原生物学]